The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Secretary of State for Health, how many people aged (a) under 18 and (b) 18 to 24 have been diagnosed with depression in each of the last five years.
Alistair Burt
This information is not held centrally.
The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Minister for the Cabinet Office, what estimate he has made of the number of people who have been diagnosed with lung cancer as a result of smoking in each of the last five years.
Mr Rob Wilson
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Secretary of State for Health, what steps the NHS takes to identify symptoms of dementia among elderly patients in hospital.
Jane Ellison
NHS England developed the Commissioning for Quality and Innovation (CQUIN) framework for 2015/16 which contains a national goal on improving dementia care. The dementia CQUIN aims to help identify patients with dementia and other causes of cognitive impairment, alongside their other medical conditions and to prompt appropriate referral and follow up after they leave hospital.
The three main aims of the CQUIN are to identify, assess and refer those presenting with symptoms of dementia. In order to identify individuals with dementia members of staff will ask members of the family or friends of a person admitted to hospital if the patient has suffered any problems with their memory in the last 12 months. If there is evidence to suggest a problem with their memory, that person will be given a dementia risk assessment and then based on the results of the assessment a referral would be made for further support either to a liaison team, a memory clinic or a general practitioner.
The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Secretary of State for Health, what recent discussions he has had with (a) pharmaceutical companies and (b) the Royal Colleges on making colchicine available on the NHS for the treatment of cancer.
George Freeman
No such discussions have taken place. We understand that a potential treatment for cancer derived from colchicine is currently in development and clinical trials are due to start in 2016.
The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Secretary of State for Health, how many people have been diagnosed with Castleman disease in each of the last five years.
George Freeman
Information on the number of diagnoses of Castleman disease is not held centrally.
The below Parliamentary question was asked by Jim Shannon on 2015-10-27.
To ask the Secretary of State for Health, what recent discussions he has had with his EU counterparts on the sale of meat and milk from cloned animals.
Jane Ellison
The sale in the European Union of meat and milk from cloned animals is subject to risk assessment under the EU Novel Foods Regulation. These Regulations are currently being revised and have been discussed at a European Council Working Group level, where the Food Standards Agency represents the United Kingdom. The European Parliament has now voted in favour of maintaining the risk assessment of products from cloned animals under the Novel Food Regulations, and the Council is expected to be asked for its formal view shortly.
The European Commission has put forward separate and more specific proposals on the cloning of farm animals and the food derived from them. The discussions on these proposals have yet to gain momentum.
There is currently no authorisation for any meat or milk from cloned animals to be in the UK food chain.
The below Parliamentary question was asked by Liam Byrne on 2015-10-27.
To ask the Secretary of State for Health, pursuant to the Answer of 19 October 2015 to Question 10693, what the rate of hospital admissions where the main reason for admission was alcohol-related was in each local authority area in (a) 2013-14, (b) 2012-13 and (c) 2011-12.
Jane Ellison
Alcohol-related hospital admissions for all local authorities are available via the Local Alcohol Profile for England (LAPE) tool at:
http://fingertips.phe.org.uk/profile/local-alcohol-profiles
The tool holds annual data from 2008/09 to 2013/14.
“
The below Parliamentary question was asked by Kirsten Oswald on 2015-10-27.
To ask the Secretary of State for Health, with reference to the Answer of 6 May 2014 to Question 196742, what progress his Department has made on assessing the effectiveness of existing arrangements for reporting complications relating to transvaginal mesh implants; and if he will make a statement.
George Freeman
The working group on vaginal tapes and mesh is now finalising its interim recommendations which NHS England expects to publish in November 2015, subject to its internal governance processes.
However in the meantime the Medicines and Healthcare products Regulatory Agency (MHRA) has unified and simplified reporting under the Yellowcard reporting brand- All reporting under one page, promoted Yellow card reporting at conferences to increase awareness e.g. RCN Congress, NICE Annual Conference; created the role of Medical Device Safety Officers in conjunction with NHS England to promote local reporting and learning.
As a result we have seen an increase in Member of Public reports relating to transvaginal mesh of 350% over 2014 so far (Table 2).
The data below is taken from the Adverse Incident Tracking System
Table 1: Adverse events reported to MHRA by health professionals concerning vaginal tape and mesh implants are as follows:
|
Vaginal tapes for stress urinary incontinence 64/25 |
Vaginal mesh for pelvic organ prolapse 64/25 |
Vaginal mesh for unknown1 indication |
|
|
2011 |
3 |
1 |
0 |
|
2012 |
23 |
31 |
2 |
|
2013 |
27 |
20 |
0 |
|
2014 |
87 |
47 |
1 |
|
Up to September 2015 |
50 |
48 |
4 |
|
1 The reporter did not provide enough information on what type of mesh it was. |
Table 2: Adverse events reported to MHRA by patients/members of the public concerning vaginal tape and mesh implants are as follows:
|
Vaginal tapes for stress urinary incontinence |
Vaginal mesh for pelvic organ prolapse |
Vaginal mesh for unknown1 indication |
|
|
2011 |
33 |
7 |
3 |
|
2012 |
26 |
2 |
0 |
|
2013 |
30 |
10 |
3 |
|
2014 |
22 |
3 |
0 |
|
Up to September 2015 |
68 |
17 |
6 |
|
1 The reporter did not provide enough information on what type of mesh it was. |
|||
“
The below Parliamentary question was asked by Andrew Gwynne on 2015-10-27.
To ask the Secretary of State for Health, what equality impact assessment has been carried out on the decision to reduce by £200 million the local government public health grant; and if he will make a statement.
Jane Ellison
The Department has conducted a public consultation exercise on the options for delivering this saving and specifically invited views in relation to the potential impact on people with protected characteristics as defined in the Equality Act 2010. We will publish our conclusions shortly.
The below Parliamentary question was asked by Dr Lisa Cameron on 2015-10-27.
To ask the Secretary of State for Health, what budget in this financial year has been assigned to providing mental health services for patients coming to terms with cancer diagnoses.
Jane Ellison
The information requested is not held, as there is no specific budget to provide mental health services to people with cancer that is reported nationally.
The Independent Cancer Taskforce published its report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020, in July this year. The mental health issues often experienced by those with cancer were highlighted in it. The Department and NHS England are currently working with partners across the health system to determine how best to take forward the recommendations of the report.